Cyclophosphamide Monohydrate
Catalog No.S2057
Molecular Weight(MW): 279.1
Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
1 Customer Review
-
Conditional patched mutant tumor cells were treated with increasing concentrations cyclophosphamide (D), alone or in combination with 10 nmol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours. Data represent means of triplicate samples ± SEM.
Cancer Res, 2013, 73(20):6310-22.. Cyclophosphamide Monohydrate purchased from Selleck.
Purity & Quality Control
Choose Selective DNA alkylator Inhibitors
Biological Activity
| Description | Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations. | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In vitro |
Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Cyclophosphamide treatment enhances apoptosis and decreases homeostatic proliferation of regulatory T cells. Cyclophosphamide downregulates the expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs).[1] Cyclophosphamide increases CYP3A4, CYP2C8, and CYP2C9 protein levels in primary human hepatocyte cultures, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes. [2] Cyclophosphamide has produced mutations in base-pair substituting strains of Salmonella tryphimurium in the presence of metabolic activation, but it has been shown to be negative in the E. coli chromotest. Cyclophosphamide has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation. [3] |
|||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||
| In vivo | Cyclophosphamide has also produced chromosome damage and micronuclei in rats, mice and Chinese hamsters, and gene mutations in the mouse spot test and in the transgenic lacZ construct of Muta Mouse. [3] Cyclophosphamide, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhances the vaccine's potential to delay tumor growth in neu transgenic mice. Cyclophosphamide mediates its effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells. [4] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 55 mg/mL (197.06 mM) |
|---|---|---|
| Water | 7 mg/mL (25.08 mM) | |
| Ethanol | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing. |
40mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 279.1 |
|---|---|
| Formula | C7H15Cl2N2O2P.H2O |
| CAS No. | 6055-19-2 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT03861403 | Recruiting | Drug: TRX518|Drug: Cyclophosphamide|Drug: Avelumab | Solid Tumors|Advanced Triple Negative Breast Cancer|Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer|Advanced Metastatic Castration-Resistant Prostate Cancer|Advanced Platinum-Resistant Ovarian Cancer | Leap Therapeutics Inc.|Pfizer|Merck KGaA Darmstadt Germany | May 20 2019 | Phase 1|Phase 2 |
| NCT03264131 | Recruiting | Drug: Brentuximab Vedotin|Drug: CHEP | Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases | UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. | October 15 2018 | Phase 2 |
| NCT03318016 | Recruiting | Drug: Cyclophosphamide | Acute Myeloid Leukemia|Relapsed/Refractory Acute Myeloid Leukemia | University of Colorado Denver | December 15 2017 | Phase 1 |
| NCT03336073 | Recruiting | Drug: Carfilzomib|Drug: Dexamethasone|Drug: cyclophosphamide | Multiple Myeloma | PETHEMA Foundation | December 18 2017 | Phase 2 |
| NCT03107988 | Recruiting | Drug: Lorlatinib|Drug: Cyclophosphamide|Drug: Topotecan | Neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California|Solving Kids'' Cancer US/EU|Children''s Neuroblastoma Cancer Foundation|The Band of Parents|The Evan Foundation|Wade''s Army|Ronan Thompson Foundation|The Catherine Elizabeth Blair Memorial Foundation|Cookies for Kids'' Cancer | September 1 2017 | Phase 1 |
| NCT03132584 | Terminated | Drug: Cyclophosphamide|Drug: Alemtuzumab | Non Hodgkin Lymphoma|High-grade B-cell Lymphoma|Diffuse Large B Cell Lymphoma | Dana-Farber Cancer Institute|Genzyme a Sanofi Company|Sanofi | July 30 2017 | Phase 1 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
-
Question 1:
Why S2057 Cyclophosphamide Monohydrate shows no activity in vitro assays?
-
Answer:
Cyclophoshamide is a prodrug and needs Pytochrome P450 to convert it to the active form: 4-hydroxy cyclophosphamide. It is widely used in vivo, if you are going to use it in vitro, you'll have to supplement Pytochrome P450 exogenously.
